Literature DB >> 35481288

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Julie Le Naour1,2,3, Zsofia Sztupinszki4,5,6, Vincent Carbonnier1,2,3, Odile Casiraghi7, Virginie Marty8, Lorenzo Galluzzi9,10,11, Zoltan Szallasi4,5,6, Guido Kroemer1,2,12,13, Erika Vacchelli1,2.   

Abstract

The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn's disease, and epidemiological associations between Crohn's disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association.
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  FPR1; Immunogenic cell death; P2RX7; radiotherapy; toll-like receptor

Mesh:

Substances:

Year:  2022        PMID: 35481288      PMCID: PMC9037530          DOI: 10.1080/2162402X.2022.2059878

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   7.723


  155 in total

1.  Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.

Authors:  Assuntina G Sacco; Ruifeng Chen; Francis P Worden; Deborah J L Wong; Douglas Adkins; Paul Swiecicki; Wanxing Chai-Ho; Peter Oppelt; Debanjali Ghosh; Julie Bykowski; Alfredo Molinolo; Emily Pittman; M Valeria Estrada; Kathryn Gold; Gregory Daniels; Scott M Lippman; Amanda Natsuhara; Karen Messer; Ezra E W Cohen
Journal:  Lancet Oncol       Date:  2021-05-11       Impact factor: 41.316

2.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Authors:  Erika Vacchelli; Yuting Ma; Elisa E Baracco; Antonella Sistigu; David P Enot; Federico Pietrocola; Heng Yang; Sandy Adjemian; Kariman Chaba; Michaela Semeraro; Michele Signore; Adele De Ninno; Valeria Lucarini; Francesca Peschiaroli; Luca Businaro; Annamaria Gerardino; Gwenola Manic; Thomas Ulas; Patrick Günther; Joachim L Schultze; Oliver Kepp; Gautier Stoll; Céline Lefebvre; Claire Mulot; Francesca Castoldi; Sylvie Rusakiewicz; Sylvain Ladoire; Lionel Apetoh; José Manuel Bravo-San Pedro; Monica Lucattelli; Cécile Delarasse; Valérie Boige; Michel Ducreux; Suzette Delaloge; Christophe Borg; Fabrice André; Giovanna Schiavoni; Ilio Vitale; Pierre Laurent-Puig; Fabrizio Mattei; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2015-10-29       Impact factor: 47.728

Review 3.  Head and neck squamous cell carcinoma in the young patient.

Authors:  David P Goldstein; Jonathan C Irish
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2005-08       Impact factor: 2.064

Review 4.  Regulation mechanisms and signaling pathways of autophagy.

Authors:  Congcong He; Daniel J Klionsky
Journal:  Annu Rev Genet       Date:  2009       Impact factor: 16.830

5.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Association Between P2RX7 Gene and Hepatocellular Carcinoma Susceptibility: A Case-Control Study in a Chinese Han Population.

Authors:  Shaobo Duan; Jie Yu; Zhiyu Han; Zhigang Cheng; Ping Liang
Journal:  Med Sci Monit       Date:  2016-06-06

Review 7.  Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.

Authors:  Weimin Lin; Miao Chen; Le Hong; Hang Zhao; Qianming Chen
Journal:  Front Oncol       Date:  2018-11-21       Impact factor: 6.244

Review 8.  Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.

Authors:  Sandra Ortiz-Cuaran; Jebrane Bouaoud; Andy Karabajakian; Jérôme Fayette; Pierre Saintigny
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

9.  PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.

Authors:  Takahiro Yamazaki; Aitziber Buqué; Tyler D Ames; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2020-02-11       Impact factor: 8.110

Review 10.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Sarah Warren; Sandy Adjemian; Patrizia Agostinis; Aitziber Buqué Martinez; Timothy A Chan; George Coukos; Sandra Demaria; Eric Deutsch; Dobrin Draganov; Richard L Edelson; Silvia C Formenti; Jitka Fucikova; Lucia Gabriele; Udo S Gaipl; Sofia R Gameiro; Abhishek D Garg; Encouse Golden; Jian Han; Kevin J Harrington; Akseli Hemminki; James W Hodge; Dewan Md Sakib Hossain; Tim Illidge; Michael Karin; Howard L Kaufman; Oliver Kepp; Guido Kroemer; Juan Jose Lasarte; Sherene Loi; Michael T Lotze; Gwenola Manic; Taha Merghoub; Alan A Melcher; Karen L Mossman; Felipe Prosper; Øystein Rekdal; Maria Rescigno; Chiara Riganti; Antonella Sistigu; Mark J Smyth; Radek Spisek; John Stagg; Bryan E Strauss; Daolin Tang; Kazuki Tatsuno; Stefaan W van Gool; Peter Vandenabeele; Takahiro Yamazaki; Dmitriy Zamarin; Laurence Zitvogel; Alessandra Cesano; Francesco M Marincola
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.